Citius Pharmaceuticals (NASDAQ:CTXR) Trading Up 7.1% – What’s Next?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)’s stock price traded up 7.1% on Monday . The company traded as high as $0.59 and last traded at $0.5786. 235,344 shares were traded during mid-day trading, a decline of 11% from the average daily volume of 265,774 shares. The stock had previously closed at $0.54.

Analyst Ratings Changes

A number of brokerages recently issued reports on CTXR. D. Boral Capital restated a “buy” rating and set a $6.00 target price on shares of Citius Pharmaceuticals in a research report on Wednesday, March 11th. Wall Street Zen lowered Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Wednesday, June 24th. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Citius Pharmaceuticals in a research report on Monday, May 18th. Finally, Zacks Research upgraded Citius Pharmaceuticals to a “hold” rating in a research note on Tuesday, May 19th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Citius Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $5.00.

Citius Pharmaceuticals Stock Up 0.7%

The business’s fifty day moving average is $0.64 and its 200-day moving average is $0.77. The stock has a market capitalization of $16.71 million, a PE ratio of -0.29 and a beta of 1.03.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.67). As a group, sell-side analysts anticipate that Citius Pharmaceuticals, Inc. will post -1.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Heights Capital Management Inc. purchased a new stake in Citius Pharmaceuticals during the fourth quarter valued at about $622,000. XTX Topco Ltd raised its holdings in shares of Citius Pharmaceuticals by 572.8% in the 4th quarter. XTX Topco Ltd now owns 107,118 shares of the company’s stock worth $83,000 after purchasing an additional 91,196 shares during the period. Asset Advisory Group Inc. acquired a new position in shares of Citius Pharmaceuticals in the 4th quarter valued at about $46,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of Citius Pharmaceuticals during the 2nd quarter worth about $40,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.